Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.

Tommaso Pianigiani, Elisa Bianchi, Giulio Natalello, Roberto Barone, Francesca Aloe, Bianca Boncompagni, Elena Bargagli, Maria Antonietta Mazzei, Carla Caffarelli, Lucia Vietri, Alberto Papi, Luca Richeldi, Fabiano Di Marco, Paolo Cameli
{"title":"Bone involvement in sarcoidosis: Insights from a multicentre Italian cohort.","authors":"Tommaso Pianigiani, Elisa Bianchi, Giulio Natalello, Roberto Barone, Francesca Aloe, Bianca Boncompagni, Elena Bargagli, Maria Antonietta Mazzei, Carla Caffarelli, Lucia Vietri, Alberto Papi, Luca Richeldi, Fabiano Di Marco, Paolo Cameli","doi":"10.36141/svdld.2026.17720","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis is a multisystemic granulomatous disease that can involve the skeletal system, although bone manifestations are considered relatively uncommon and often underdiagnosed.</p><p><strong>Objectives: </strong>To describe the prevalence, clinical characteristics, and treatment outcomes of bone involvement in a large multicenter Italian cohort of patients with sarcoidosis.</p><p><strong>Methods: </strong> This retrospective, two-center observational study included 867 patients with histologically confirmed sarcoidosis followed at two Italian referral centers (2018-2025). Bone localization was identified by imaging (PET/CT, MRI, X-ray) and/or biopsy. Clinical, functional, laboratory, and therapeutic data were collected.</p><p><strong>Results: </strong>Bone involvement was found in 46 patients (5.3%), predominantly women (58.7%), with mean age at diagnosis of 49.7 ± 12.2 years. Osseous lesions were most frequently localized in the axial skeleton, particularly pelvis (54.3%) and vertebrae (52.2%). Bone sarcoidosis was significantly associated with extra-thoracic lymphadenopathy, hepatic, and splenic involvement (p < 0.001), reflecting a pattern of clustered multi-organ disease. Osteoporosis and osteopenia were present in 15.2% and 13.0% of cases, respectively. Corticosteroid monotherapy was the most common initial treatment (56.5%), while 30.4% received combination therapy with csDMARDs or biologics. At one-year PET/CT re-evaluation, 56.5% showed a reduction of SUV at bone sites, with no significant correlation between therapeutic regimen and metabolic response.</p><p><strong>Conclusions: </strong>Bone involvement in sarcoidosis, though relatively rare, represents a clinically relevant phenotype strongly associated with hepatosplenic and lymphatic disease and characterized by a preferential axial skeleton localization. Recognition of this pattern is essential for diagnosis and management. Given the retrospective design and the limited follow-up sample, these findings should be interpreted with caution. Close radiological monitoring and tailored therapeutic strategies are warranted to improve outcomes.</p>","PeriodicalId":502142,"journal":{"name":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","volume":"43 2","pages":"17720"},"PeriodicalIF":0.0000,"publicationDate":"2026-06-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13358992/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36141/svdld.2026.17720","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Sarcoidosis is a multisystemic granulomatous disease that can involve the skeletal system, although bone manifestations are considered relatively uncommon and often underdiagnosed.

Objectives: To describe the prevalence, clinical characteristics, and treatment outcomes of bone involvement in a large multicenter Italian cohort of patients with sarcoidosis.

Methods:  This retrospective, two-center observational study included 867 patients with histologically confirmed sarcoidosis followed at two Italian referral centers (2018-2025). Bone localization was identified by imaging (PET/CT, MRI, X-ray) and/or biopsy. Clinical, functional, laboratory, and therapeutic data were collected.

Results: Bone involvement was found in 46 patients (5.3%), predominantly women (58.7%), with mean age at diagnosis of 49.7 ± 12.2 years. Osseous lesions were most frequently localized in the axial skeleton, particularly pelvis (54.3%) and vertebrae (52.2%). Bone sarcoidosis was significantly associated with extra-thoracic lymphadenopathy, hepatic, and splenic involvement (p < 0.001), reflecting a pattern of clustered multi-organ disease. Osteoporosis and osteopenia were present in 15.2% and 13.0% of cases, respectively. Corticosteroid monotherapy was the most common initial treatment (56.5%), while 30.4% received combination therapy with csDMARDs or biologics. At one-year PET/CT re-evaluation, 56.5% showed a reduction of SUV at bone sites, with no significant correlation between therapeutic regimen and metabolic response.

Conclusions: Bone involvement in sarcoidosis, though relatively rare, represents a clinically relevant phenotype strongly associated with hepatosplenic and lymphatic disease and characterized by a preferential axial skeleton localization. Recognition of this pattern is essential for diagnosis and management. Given the retrospective design and the limited follow-up sample, these findings should be interpreted with caution. Close radiological monitoring and tailored therapeutic strategies are warranted to improve outcomes.

结节病的骨受累:来自意大利多中心队列的见解。
背景:结节病是一种多系统肉芽肿性疾病,可累及骨骼系统,尽管骨骼表现相对罕见且常被误诊。目的:描述意大利一个大型多中心队列结节病患者骨骼受累的患病率、临床特征和治疗结果。方法:这项回顾性、双中心观察性研究纳入了867例组织学证实的结节病患者,随访于意大利两家转诊中心(2018-2025)。通过成像(PET/CT, MRI, x线)和/或活检确定骨定位。收集临床、功能、实验室和治疗数据。结果:骨受累46例(5.3%),以女性为主(58.7%),平均诊断年龄49.7±12.2岁。骨性病变最常局限于中轴骨骼,尤其是骨盆(54.3%)和椎骨(52.2%)。骨结节病与胸外淋巴结病、肝脏和脾脏受累显著相关(p < 0.001),反映了一种聚集性多器官疾病的模式。骨质疏松和骨质减少分别占15.2%和13.0%。皮质类固醇单药治疗是最常见的初始治疗(56.5%),而30.4%的患者接受csDMARDs或生物制剂联合治疗。在一年的PET/CT重新评估中,56.5%的患者显示骨部位SUV减少,治疗方案与代谢反应之间无显著相关性。结论:结节病的骨骼受累虽然相对罕见,但代表了一种与肝脾和淋巴疾病密切相关的临床相关表型,其特征是优先轴向骨骼定位。认识到这种模式对诊断和治疗至关重要。考虑到回顾性设计和有限的随访样本,这些发现应谨慎解释。密切的放射监测和量身定制的治疗策略是必要的,以改善结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书